DLBCL 1L—What to Expect beyond R-CHOP?

SIMPLE SUMMARY: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma. About two-thirds of patients are cured by the first-line (1L) standard of care (SOC), the R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone) immunochemotherapy pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Stegemann, Maike, Denker, Sophy, Schmitt, Clemens A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946010/
https://www.ncbi.nlm.nih.gov/pubmed/35326604
http://dx.doi.org/10.3390/cancers14061453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946010/
https://www.ncbi.nlm.nih.gov/pubmed/35326604
http://dx.doi.org/10.3390/cancers14061453

Ejemplares similares